Pasithea Therapeutics Corp.
KTTA
$0.57
-$0.03-4.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.03M | 1.93M | 3.35M | 1.75M | 1.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.71M | 4.88M | 6.09M | 3.11M | 3.81M |
| Operating Income | -5.71M | -4.88M | -6.09M | -3.11M | -3.81M |
| Income Before Tax | -5.27M | -2.87M | -10.11M | -3.04M | -3.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.27M | -2.87M | -10.11M | -3.04M | -3.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.27M | -2.87M | -10.11M | -3.04M | -3.72M |
| EBIT | -5.71M | -4.88M | -6.09M | -3.11M | -3.81M |
| EBITDA | -5.56M | -4.72M | -5.93M | -2.93M | -3.65M |
| EPS Basic | -0.16 | -0.12 | -0.79 | -0.41 | -0.66 |
| Normalized Basic EPS | -0.10 | -0.07 | -0.29 | -0.26 | -0.41 |
| EPS Diluted | -0.16 | -0.12 | -0.79 | -0.41 | -0.66 |
| Normalized Diluted EPS | -0.10 | -0.07 | -0.29 | -0.26 | -0.41 |
| Average Basic Shares Outstanding | 32.10M | 24.34M | 12.77M | 7.44M | 5.64M |
| Average Diluted Shares Outstanding | 32.10M | 24.34M | 12.77M | 7.44M | 5.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |